Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

RxSight (RXST) EPS (Weighted Average and Diluted) (2020 - 2026)

RxSight filings provide 6 years of EPS (Weighted Average and Diluted) readings, the most recent being -$0.22 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 46.67% to -$0.22 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.95, a 31.94% decrease, with the full-year FY2025 number at -$0.95, down 33.8% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.22 in Q4 2025 for RxSight, up from -$0.24 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.09 in Q4 2021 to a low of -$3.53 in Q2 2021.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.29 (2025), compared with a mean of -$0.51.
  • The widest YoY moves for EPS (Weighted Average and Diluted): up 82.72% in 2022, down 711.11% in 2022.
  • RxSight's EPS (Weighted Average and Diluted) stood at $0.09 in 2021, then plummeted by 711.11% to -$0.55 in 2022, then surged by 54.55% to -$0.25 in 2023, then soared by 40.0% to -$0.15 in 2024, then tumbled by 46.67% to -$0.22 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.22 (Q4 2025), -$0.24 (Q3 2025), and -$0.29 (Q2 2025) per Business Quant data.